After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...

The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

The likelihood of antiviral prescribing and dispensing among patients with influenza varied by care setting, patient age, and underlying medical conditions.

US president Donald Trump is up to his old tricks, threatening to inflict enormous tariffs as part of an ultimatum that could end up hitting Australians with a huge price hike on essential items.

Bil Schmidtknecht blames pharmacy benefit managers for the death of his son. He won’t rest until he holds them accountable.